US6136814A
(en)
*
|
1997-12-08 |
2000-10-24 |
Fujisawa Usa, Inc. |
Aqueous acyclovir product
|
SE9801704D0
(sv)
*
|
1998-05-14 |
1998-05-14 |
Bioglan Ab |
Biologically active composition
|
SE9801705D0
(sv)
*
|
1998-05-14 |
1998-05-14 |
Bioglan Ab |
Biologically active composition
|
EP1216037A2
(en)
*
|
1999-09-21 |
2002-06-26 |
Emory University |
Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
|
JP5767429B2
(ja)
*
|
1999-11-12 |
2015-08-19 |
アッヴィ・インコーポレイテッド |
固体分散剤中の結晶化阻害剤
|
US7364752B1
(en)
|
1999-11-12 |
2008-04-29 |
Abbott Laboratories |
Solid dispersion pharamaceutical formulations
|
DE10026698A1
(de)
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
|
JP4512700B2
(ja)
*
|
2003-06-02 |
2010-07-28 |
トーアエイヨー株式会社 |
アシクロビル含有水溶液製剤
|
US8377952B2
(en)
*
|
2003-08-28 |
2013-02-19 |
Abbott Laboratories |
Solid pharmaceutical dosage formulation
|
US8025899B2
(en)
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
US20050101605A1
(en)
*
|
2003-11-07 |
2005-05-12 |
Ahmed Salah U. |
Oral liquid formulations of methotrexate
|
JP4896006B2
(ja)
|
2004-04-08 |
2012-03-14 |
バイオマトリカ, インコーポレイテッド |
ライフサイエンスのためのサンプル保存とサンプル管理との統合
|
EA017290B1
(ru)
|
2005-11-28 |
2012-11-30 |
Домейн Раша Инвестментс Лимитед |
Композиции на основе ганаксолона
|
GB2432528B
(en)
*
|
2005-11-29 |
2011-04-06 |
Ian Ripley |
Anti-viral compositions comprising flavanone glycosides and fruit acids
|
WO2007102243A1
(ja)
|
2006-03-08 |
2007-09-13 |
Nihon Nohyaku Co., Ltd. |
外用の医薬組成物
|
US8349882B2
(en)
*
|
2006-03-08 |
2013-01-08 |
Nihon Nohyaku Co., Ltd. |
Pharmaceutical composition for external use
|
RU2419429C2
(ru)
*
|
2006-03-08 |
2011-05-27 |
Нихон Нохияку Ко.,Лтд. |
Фармацевтическая композиция для наружного применения
|
AU2007260739A1
(en)
*
|
2006-06-14 |
2007-12-21 |
Dr. Reddy's Laboratories Limited |
Topical compositions
|
EP2081435B1
(en)
|
2006-09-22 |
2016-05-04 |
Pharmacyclics LLC |
Inhibitors of bruton's tyrosine kinase
|
KR100721126B1
(ko)
|
2006-12-28 |
2007-05-23 |
(주)바이오앤에이치엔티 |
모기 기피제 조성물
|
CN101808637B
(zh)
*
|
2007-09-05 |
2013-07-24 |
宝丽制药股份有限公司 |
医药组合物
|
JP5453093B2
(ja)
*
|
2007-09-05 |
2014-03-26 |
株式会社ポーラファルマ |
抗真菌医薬組成物
|
JP5345937B2
(ja)
*
|
2007-09-05 |
2013-11-20 |
株式会社ポーラファルマ |
抗真菌組成物
|
CA2699157A1
(en)
|
2007-09-10 |
2009-03-19 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
JP5421901B2
(ja)
|
2008-03-31 |
2014-02-19 |
国立大学法人広島大学 |
エンテロウイルス属の非エンベロープウイルスに対する抗ウイルス剤および抗ウイルス用組成物
|
GB2462022B
(en)
|
2008-06-16 |
2011-05-25 |
Biovascular Inc |
Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
|
MX2011002149A
(es)
|
2008-08-27 |
2011-04-05 |
Calcimedica Inc |
Compuestos que modulan el calcio intracelular.
|
EP2385821B1
(en)
*
|
2009-01-09 |
2016-08-31 |
Egis Gyógyszergyár Zrt. |
Improved pharmaceutical formulation
|
EP2745692A1
(en)
*
|
2009-02-13 |
2014-06-25 |
Topica Pharmaceuticals, Inc |
anti-fungal formulation containing luliconazole
|
US10130610B2
(en)
|
2009-04-09 |
2018-11-20 |
Pola Pharma Inc. |
Antimycotic pharmaceutical composition
|
EP2416758B8
(en)
|
2009-04-09 |
2017-10-18 |
Pola Pharma Inc. |
Antimycotic pharmaceutical composition
|
CN102481286B
(zh)
|
2009-08-25 |
2014-02-26 |
宝丽制药股份有限公司 |
抗真菌药物组合物
|
US7741330B1
(en)
|
2009-10-12 |
2010-06-22 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
|
EP2558866B1
(en)
|
2010-04-15 |
2016-08-17 |
Tracon Pharmaceuticals, Inc. |
Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
|
WO2011139489A2
(en)
|
2010-04-27 |
2011-11-10 |
Calcimedica Inc. |
Compounds that modulate intracellular calcium
|
AU2011248579A1
(en)
|
2010-04-27 |
2012-11-29 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
WO2012018638A2
(en)
|
2010-07-26 |
2012-02-09 |
Biomatrica, Inc. |
Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
|
US9845489B2
(en)
|
2010-07-26 |
2017-12-19 |
Biomatrica, Inc. |
Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
|
US9079891B2
(en)
|
2010-08-27 |
2015-07-14 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
US9512116B2
(en)
|
2012-10-12 |
2016-12-06 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
WO2014100755A2
(en)
|
2012-12-20 |
2014-06-26 |
Biomatrica, Inc. |
Formulations and methods for stabilizing pcr reagents
|
WO2015054283A1
(en)
|
2013-10-08 |
2015-04-16 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
WO2015084998A1
(en)
|
2013-12-05 |
2015-06-11 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
US20150224078A1
(en)
|
2014-02-10 |
2015-08-13 |
Patara Pharma, LLC |
Methods for the Treatment of Lung Diseases with Mast Cell Stabilizers
|
SI3104853T1
(sl)
|
2014-02-10 |
2020-03-31 |
Respivant Sciences Gmbh |
Zdravljenje s stabilizatorji mastocitov za sistemske motnje
|
WO2015164213A1
(en)
|
2014-04-23 |
2015-10-29 |
The Research Foundation For The State University Of New York |
A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
|
ES2786373T3
(es)
|
2014-06-10 |
2020-10-09 |
Biomatrica Inc |
Estabilización de trombocitos a temperaturas ambiente
|
US9839644B2
(en)
|
2014-09-09 |
2017-12-12 |
ARKAY Therapeutics, LLC |
Formulations and methods for treatment of metabolic syndrome
|
US9359316B1
(en)
|
2014-11-25 |
2016-06-07 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
JP2018510138A
(ja)
|
2015-02-27 |
2018-04-12 |
カーテナ ファーマシューティカルズ,インク. |
Olig2活性の阻害
|
WO2017027402A1
(en)
|
2015-08-07 |
2017-02-16 |
Patara Pharma, LLC |
Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
|
US10238625B2
(en)
|
2015-08-07 |
2019-03-26 |
Respivant Sciences Gmbh |
Methods for the treatment of mast cell related disorders with mast cell stabilizers
|
ES2946184T3
(es)
|
2015-12-08 |
2023-07-13 |
Biomatrica Inc |
Reducción de la velocidad de eritrosedimentación
|
WO2017147146A1
(en)
|
2016-02-23 |
2017-08-31 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic trpv1 agonists
|
ES2910787T3
(es)
|
2016-05-12 |
2022-05-13 |
Univ Michigan Regents |
Inhibidores de ASH1L y métodos de tratamiento con los mismos
|
US10821105B2
(en)
|
2016-05-25 |
2020-11-03 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
|
WO2017205766A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205762A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205769A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
JP7028860B2
(ja)
|
2016-08-26 |
2022-03-02 |
カーテナ ファーマシューティカルズ,インク. |
Olig2活性の阻害
|
CA3035528A1
(en)
|
2016-08-31 |
2018-03-08 |
Respivant Sciences Gmbh |
Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
|
EP3522983A4
(en)
|
2016-10-07 |
2020-06-03 |
Respivant Sciences GmbH |
CROMOLYNE-BASED COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS
|
WO2019094434A1
(en)
|
2017-11-07 |
2019-05-16 |
The Regents Of The University Of Michigan |
Therapeutic combination for treatment of cerebellar ataxia
|
WO2019094773A1
(en)
|
2017-11-10 |
2019-05-16 |
The Regents Of The University Of Michigan |
Ash1l inhibitors and methods of treatment therewith
|
CN112040947A
(zh)
|
2017-12-07 |
2020-12-04 |
密歇根大学董事会 |
Nsd家族抑制剂及用其进行治疗的方法
|
US11685722B2
(en)
|
2018-02-28 |
2023-06-27 |
Curtana Pharmaceuticals, Inc. |
Inhibition of Olig2 activity
|
US11319302B2
(en)
|
2018-06-07 |
2022-05-03 |
The Regents Of The University Of Michigan |
PRC1 inhibitors and methods of treatment therewith
|
WO2020023794A1
(en)
|
2018-07-27 |
2020-01-30 |
Concentric Analgesics, Inc. |
Pegylated prodrugs of phenolic trpv1 agonists
|
GB2591681A
(en)
|
2018-08-29 |
2021-08-04 |
Ftf Pharma Private Ltd |
Methotrexate pharmaceutical composition
|
US20200069742A1
(en)
|
2018-08-29 |
2020-03-05 |
Myos Rens Technology Inc. |
Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
|
US20200108102A1
(en)
|
2018-10-03 |
2020-04-09 |
Myos Rens Technology Inc. |
Spray dried follistatin product
|
WO2020085904A2
(en)
|
2018-10-24 |
2020-04-30 |
SeraNovo B.V. |
Deep eutectic solvent platform for oral pharmaceutical formulations
|
NL2021864B1
(en)
*
|
2018-10-24 |
2020-05-13 |
Seranovo B V |
Deep Eutectic Solvent Platform for Oral Pharmaceutical Formulations
|
WO2020096660A1
(en)
|
2018-11-06 |
2020-05-14 |
Myos Rens Technology, Inc. |
Methods and compositions for improving skeletal muscle protein fractional synthetic rate
|
MX2021007925A
(es)
|
2018-12-31 |
2021-10-26 |
Biomea Fusion Llc |
Inhibidores irreversibles de la interaccion menina-mll.
|
US11833186B2
(en)
|
2019-02-01 |
2023-12-05 |
Myos Corp. |
Methods and compositions for improving quality of life and increasing activity in aging and chronically ill mammals
|
WO2020190890A1
(en)
|
2019-03-15 |
2020-09-24 |
Unicycive Therapeutics Inc. |
Nicorandil derivatives
|
CN116113406A
(zh)
|
2020-07-10 |
2023-05-12 |
密歇根大学董事会 |
Gas41抑制剂及其使用方法
|
CA3202151A1
(en)
|
2020-12-16 |
2022-06-23 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin-mll interaction
|
WO2023018825A1
(en)
|
2021-08-11 |
2023-02-16 |
Biomea Fusion, Inc. |
Covalent inhibitors of menin-mll interaction for diabetes mellitus
|
WO2023027966A1
(en)
|
2021-08-24 |
2023-03-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as irreversible inhibitors of flt3
|
WO2023039240A1
(en)
|
2021-09-13 |
2023-03-16 |
Biomea Fusion, Inc. |
IRREVERSIBLE INHIBITORS OF KRas
|
WO2023086341A1
(en)
|
2021-11-09 |
2023-05-19 |
Biomea Fusion, Inc. |
Inhibitors of kras
|
US11945785B2
(en)
|
2021-12-30 |
2024-04-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as inhibitors of FLT3
|
WO2023235618A1
(en)
|
2022-06-03 |
2023-12-07 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin
|